JRC Publications Repository

JRC Publications Repository >

Browsing by Author SCHWAIGER M.

Sort by: In order: Results/Page Authors/Record:
Showing results 1 to 10 of 10
Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2007213bi-Induced Death of Hsc45-M2 Gastric Cancer Cells Is Characterized by G2 Arrest and Up-Regulation of Genes Known to Prevent Apoptosis but Induce Necrosis and Mitotic CatastrpopheSEIDL C.; PORT M.; GILBERTZ K.; MORGENSTERN ALFRED; BRUCHERTSEIFER FRANK; SCHWAIGER M.; ROEPER B.; SENEKOWITSCH-SCHMIDTKE R.; ABEND M.Articles in Journals
2007213Bi-radioimmunotherapy Defeats Early-stage Disseminated Gastric Cancer in Nude MiceBECK R.; SEIDL C.; PFOST B.; MORGENSTERN ALFRED; BRUCHERTSEIFER FRANK; BAUM M.; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.Articles in Journals
2000Binding of a Bi-213 Labeled Monoclonal Antibody Targeting a Tumor Specific Mutant E-Cadherin in Different Tumor Models.ADAM C.; SCHUHMACHER C.; BECKER K.; HANDSCHUH G.; NIKULA T.; APOSTOLIDIS Christos; FISCHER K.; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.Contributions to Conferences
2005Cell Death Triggered by Alpha-emitting 213Bi-immunoconjugates in HSC45-M2 Gastric Cancer Cells is different from Apoptotic Cell Death.SEIDL C.; SCHROECK H.; SEIDENSCHWANG S.; BECK R.; SCHMID E.; ABEND M.; BECKER K.-F.; APOSTOLIDIS CHRISTOS; NIKULA Tuomo; KREMMER E., et alArticles in Journals
2010Differential Gene Expression Triggered by Highly Cytotoxic a- Emitter-immunoconjugates in Gastric Cancer CellsSEIDL C.; PORT M.; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.; ABEND M.Articles in Journals
2005Fractionated Locoregional Low-Dose Radioimmunotherapy Improves Survival in a Mouse Model of Diffuse Type Gastric Cancer Using A 213BI-conjugated Monoclonal AntibodyBLOECHEL S.; BECK R.; SEIDL C.; MORGENSTERN ALFRED; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.Articles in Journals
2001Highly Specific Tumor Binding of a 213Bi Labeled Monoclonal Antibody against Mutant E-Cadherin Suggests its Usefulness for Locoregional alpha-Radioimmunotherapy of Diffuse-Type Gastric Cancer.SENEKOWITSCH-SCHMIDTKE R.; SCHUHMACHER C.; BECKER K.; NIKULA T.k.; SEIDL C.; BECKER I.; MIEDERER M.; APOSTOLIDIS Christos; ADAM C.; HUBER Roswitha, et alArticles in Journals
2007Non-invasive Visualisation of the Development of Peritoneal Carcinomatosis and Tumour Regression After 213Bi-radioimmunotherapy Using Bioluminescence ImagingBUCHHORN H.m.; SEIDL C.; BECK R.; SAUR D.; APOSTOLIDIS CHRISTOS; MORGENSTERN ALFRED; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.Articles in Journals
2000Tumor Binding and Therapeutic Efficacy of 213-Bi Labeled Mutation Specific Monoclonal Antobody in a Human Intraperitoneal Gastric Cancer Model.SENEKOWITSCH-SCHMIDTKE R.; FISCHER K.; SCHUMACHER C.; BECKER I.; BECKER K.; APOSTOLIDIS Christos; NIKULA T.; SCHWAIGER M.Contributions to Conferences
2004Underground Measurements Radioactivity.LAUBENSTEIN Matthias; HULT Mikael; GASPARRO Joel; ARNOLD D.; NEUMAIER Stefan; HEUSSER G.; KOEHLER M.; POVINEC P.; REYSS Jean louis; SCHWAIGER M., et alContributions to Conferences
Showing results 1 to 10 of 10

 

The mission of the JRC is to provide customer-driven scientific and technical support for the conception, development, implementation and monitoring of EU policies. As a service of the European Commission, the JRC functions as a reference centre of science and technology for the Union. Close to the policy-making process, it serves the common interest of the Member States, while being independent of special interests, whether private or national.
Powered by DSpace
Top